Cullinan Therapeutics, Inc. (CGEM)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$14.37-3.69%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cullinan Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	13M
EPS	—	-0.714
Annual ending 2026-12-31
Revenue	—	12.62M
EPS	—	-3.173
Annual ending 2027-12-31
Revenue	—	57.84M
EPS	—	-2.5

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash runway extended into 2029	The company has cash to last into 2029.	Intact	Cash resources fall below level needed to fund operations into 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance CLN-978 clinical trials in RA and SLE	Cullinan is advancing its CLN-978 clinical trials for tough autoimmune diseases.	Intact	Trial progress stalls or clinical data fails to show benefit	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 disclosures including 2026-Q1 and 2026-09-24 press releases. Management plans multiple clinical data presentations and multi-dose regimen studies for CLN-978 across autoimmune indications in 2026. The trajectory shows ongoing clinical development progress with upcoming data milestones. Delivery assessment Oct 24, 2026
Reduce losses in EPS	A supporting condition in Cullinan Therapeutics, Inc.'s published investment case. The stated target is EPS loss less than -$3.0 in FY26 and improving in FY27.	Intact	EPS loss worsens beyond -$3.0 in FY26 or FY27	Diluted EPS: $-0.81 per share FY2026-Q2; GAAP. Published target: EPS loss less than -$3.0 in FY26 and improving in FY27. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.81 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.50

$-2.53 → $-2.50 · observed estimates

FY2027 revenue$0.06B

$0.04B → $0.06B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.53	$40,391,550	8 / 10
2026-07-25	$-2.53	$40,391,550	8 / 10
2026-07-26	$-2.53	$40,391,550	8 / 10
2026-07-27	$-2.53	$40,391,550	8 / 10
2026-07-28	$-2.53	$40,391,550	8 / 10
2026-07-29	$-2.53	$40,391,550	8 / 10
2026-07-30	$-2.41	$47,709,462	7 / 7
2026-07-31	$-2.53	$40,391,550	8 / 10
2026-08-01	$-2.53	$40,391,550	8 / 10
2026-08-02	$-2.53	$40,391,550	8 / 10
2026-08-03	$-2.41	$47,709,462	7 / 7
2026-08-04	$-2.41	$47,709,462	7 / 7
2026-08-05	$-2.41	$47,709,462	7 / 7
2026-08-06	$-2.41	$47,709,462	7 / 7
2026-08-07	$-2.41	$47,709,462	7 / 7
2026-08-08	$-2.41	$47,709,462	7 / 7
2026-08-09	$-2.41	$47,709,462	7 / 7
2026-08-10	$-2.41	$47,709,462	7 / 7
2026-08-11	$-2.54	$50,519,440	8 / 8
2026-08-12	$-2.41	$47,709,462	7 / 7
2026-08-13	$-2.41	$47,709,462	7 / 7
2026-08-14	$-2.41	$47,709,462	7 / 7
2026-08-15	$-2.41	$47,709,462	8 / 7
2026-08-16	$-2.41	$47,709,462	8 / 7
2026-08-17	$-2.41	$47,709,462	8 / 7
2026-08-18	$-2.41	$47,709,462	8 / 7
2026-08-19	$-2.41	$47,709,462	8 / 7
2026-08-20	$-2.62	$45,521,446	8 / 8
2026-08-21	$-2.62	$45,521,446	8 / 8
2026-08-22	$-2.62	$45,521,446	8 / 8
2026-08-23	$-2.62	$45,521,446	8 / 8
2026-08-24	$-2.62	$45,521,446	8 / 8
2026-08-25	$-2.62	$45,521,446	8 / 8
2026-08-26	$-2.62	$45,521,446	8 / 8
2026-08-27	$-2.62	$45,521,446	8 / 8
2026-08-28	$-2.62	$45,521,446	8 / 8
2026-08-29	$-2.62	$45,521,446	8 / 8
2026-08-30	$-2.62	$45,521,446	8 / 8
2026-08-31	$-2.62	$45,521,446	8 / 8
2026-09-01	$-2.62	$45,521,446	8 / 8
2026-09-02	$-2.62	$45,521,446	8 / 8
2026-09-03	$-2.62	$45,521,446	8 / 8
2026-09-04	$-2.62	$45,521,446	8 / 8
2026-09-05	$-2.62	$45,521,446	8 / 8
2026-09-06	$-2.62	$45,521,446	8 / 8
2026-09-07	$-2.62	$45,521,446	8 / 8
2026-09-08	$-2.62	$45,521,446	8 / 8
2026-09-09	$-2.62	$45,521,446	8 / 8
2026-09-10	$-2.62	$45,521,446	8 / 8
2026-09-11	$-2.62	$45,521,446	8 / 8
2026-09-12	$-2.62	$45,521,446	8 / 8
2026-09-13	$-2.62	$45,521,446	8 / 8
2026-09-14	$-2.62	$45,521,446	8 / 8
2026-09-15	$-2.62	$45,521,446	8 / 8
2026-09-16	$-2.60	$47,829,139	8 / 8
2026-09-17	$-2.60	$47,829,139	8 / 8
2026-09-18	$-2.60	$47,829,139	8 / 8
2026-09-19	$-2.60	$47,829,139	8 / 8
2026-09-20	$-2.60	$47,829,139	8 / 8
2026-09-21	$-2.60	$47,829,139	8 / 8
2026-09-22	$-2.60	$47,829,139	8 / 8
2026-09-23	$-2.60	$47,829,139	8 / 8
2026-09-24	$-2.60	$47,829,139	8 / 8
2026-09-25	$-2.60	$47,829,139	8 / 8
2026-09-26	$-2.66	$47,838,292	8 / 8
2026-09-27	$-2.66	$47,838,292	8 / 8
2026-09-28	$-2.66	$47,838,292	8 / 8
2026-09-29	$-2.66	$47,838,292	8 / 8
2026-09-30	$-2.66	$47,838,292	8 / 8
2026-10-01	$-2.66	$47,838,292	8 / 8
2026-10-02	$-2.66	$47,838,292	8 / 8
2026-10-03	$-2.50	$57,838,292	8 / 8
2026-10-04	$-2.50	$57,838,292	8 / 8
2026-10-05	$-2.50	$57,838,292	8 / 8
2026-10-06	$-2.50	$57,838,292	8 / 8
2026-10-07	$-2.50	$57,838,292	8 / 8
2026-10-08	$-2.50	$57,838,292	8 / 8
2026-10-09	$-2.50	$57,838,292	8 / 8
2026-10-10	$-2.50	$57,838,292	8 / 8
2026-10-11	$-2.50	$57,838,292	8 / 8
2026-10-12	$-2.50	$57,838,292	8 / 8
2026-10-13	$-2.50	$57,838,292	8 / 8
2026-10-14	$-2.50	$57,838,292	8 / 8
2026-10-15	$-2.50	$57,838,292	8 / 8
2026-10-16	$-2.50	$57,838,292	8 / 8
2026-10-17	$-2.50	$57,838,292	8 / 8
2026-10-18	$-2.50	$57,838,292	8 / 8
2026-10-19	$-2.50	$57,838,292	8 / 8
2026-10-20	$-2.50	$57,838,292	8 / 8
2026-10-21	$-2.50	$57,838,292	8 / 8
2026-10-22	$-2.50	$57,838,292	8 / 8
2026-10-23	$-2.50	$57,838,292	8 / 8
2026-10-24	$-2.50	$57,838,292	8 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	0	0
2026-06-01	12	0	0
2026-07-01	12	0	0
2026-08-01	12	0	0
2026-09-01	12	0	0
2026-10-01	12	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightSep 25 · prior Apr 28

$30.00 → $35.00+16.7%

$0$19.25$38.50

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash runway extended into 2029Direct metric needs a verified mapping
Advance CLN-978 clinical trials in RA and SLEDirect metric needs a verified mapping
Reduce losses in EPSDiluted EPS: $-0.81 per share

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-43.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cullinan Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CGEM is a speculative, clinical-stage biotechnology company, so its multi-year case depends on development and regulatory milestones rather than established earnings. The thesis is in a watch state, and confidence in the overall read is low.

What's priced into Cullinan Therapeutics, Inc.

The evidence gives no valuation measure or clear account of what the market already assumes, so whether CGEM is cheap or expensive versus peers cannot be assessed. No valuation fragility signals fired, but that does not resolve the expectations gap.

What the fundamentals likely do

Near term, performance is mixed: CGEM had an earnings miss in August, and its recent financial performance is below its industry cohort. Management is pursuing a zipalertinib NDA submission by year-end 2026, with a stated regulatory milestone in February 2027, while clinical data milestones for CLN-978 and velinotamig are forthcoming. The next print carries elevated miss risk, and guidance cuts would be a meaningful negative.

What Cullinan Therapeutics, Inc. hinges on

The multi-year thesis hinges on progress toward U.S. approval for zipalertinib and useful clinical data for the autoimmune programs. Near-term risks include a guidance cut and weakening employment data, while continued strong results and higher guidance from sector bellwethers could support the healthcare backdrop.